Journal of Neuro-Oncology

, Volume 103, Issue 3, pp 797–801

mTORC1 activation in childhood ependymoma and response to sirolimus

  • Daniel C. Bowers
  • Blanka Kucejova
  • Linda Margraf
  • Lynn Gargan
  • James Brugarolas
Case Report

DOI: 10.1007/s11060-010-0455-7

Cite this article as:
Bowers, D.C., Kucejova, B., Margraf, L. et al. J Neurooncol (2011) 103: 797. doi:10.1007/s11060-010-0455-7

Abstract

Recurrent ependymomas are considered rarely responsive to chemotherapy and often have a dismal prognosis after tumor progression. Below is a brief report of a 6 year old child with a multiply progressive ependymoma whose tumor had a near complete response to sirolimus that was durable for 18 months. Immunohistochemistry for phosphorylated S6, which has been reported to be associated with tumor sensitivity to mTORC1 inhibitors, was positive in this patient’s tumor.

Keywords

EpendymomaSirolimusRapamycinmTORC1

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Daniel C. Bowers
    • 1
    • 4
    • 6
    • 7
  • Blanka Kucejova
    • 2
    • 3
    • 4
  • Linda Margraf
    • 5
  • Lynn Gargan
    • 6
  • James Brugarolas
    • 3
    • 4
    • 5
  1. 1.Department of PediatricsUniversity of Texas Southwestern Medical School at DallasDallasUSA
  2. 2.Department of Internal MedicineUniversity of Texas Southwestern Medical School at DallasDallasUSA
  3. 3.Department of Developmental BiologyUniversity of Texas Southwestern Medical School at DallasDallasUSA
  4. 4.Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical School at DallasDallasUSA
  5. 5.Department of PathologyUniversity of Texas Southwestern Medical School at DallasDallasUSA
  6. 6.Department of Neuro-OncologyCenter for Cancer and Blood Disorders, Children’s Medical Center – DallasDallasUSA
  7. 7.Division of Pediatric Hematology-OncologyUniversity of Texas Southwestern Medical School at DallasDallasUSA